All In Biotech

Drug Trial Radar · NCT07602127

Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy

Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of AGX-08 in Geographic Atrophy

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Augelux TherapeuticsIndustry
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.

Conditions

  • Geographic Atrophy

Interventions

  • AGX-08-LDrug

    rAAV2.AG-eNCRV intravitreal injection of low dose

  • AGX-08-HDrug

    rAAV2.AG-eNCRV intravitreal injection of high dose

  • AGX-08-SProcedure

    sham intravitreal injection of AGX-08 (not actual injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events,adverse events, serious adverse events and dose-limiting toxicitiesTime frame: baseline to Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.